Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2009 May 20;27(15):2466-73.
doi: 10.1200/JCO.2008.19.8424. Epub 2009 Apr 6.

Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer

Stewart J Anderson  1 , Irene Wapnir, James J Dignam, Bernard Fisher, Eleftherios P Mamounas, Jong-Hyeon Jeong, Charles E Geyer Jr, D Lawrence Wickerham, Joseph P Costantino, Norman Wolmark
Affiliations
Randomized Controlled Trial

Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer

Stewart J Anderson et al. J Clin Oncol. .

Abstract

Purpose: Locoregional failure (LRF) after breast-conserving therapy (BCT) is associated with increased risk of distant disease and death. The magnitude of this risk has not been adequately characterized in patients with lymph node-negative disease.

Patients and methods: Our study population included 3,799 women randomly assigned to five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative disease (ie, B-13, B-14, B-19, B-20, and B-23) who underwent lumpectomy and whole breast irradiation with or without adjuvant systemic therapy. Cumulative incidences of ipsilateral breast tumor recurrence (IBTR) and other locoregional recurrence (oLRR) were calculated, along with distant-disease-free interval (DDFI) and overall survival (OS) after these events. Cox models were employed to model mortality by using clinical and pathologic factors jointly with these events.

Results: Four hundred nineteen patients (11.0%) experienced LRF: 342 (9.0%) experienced IBTR, and 77 (2.0%) experienced oLRR. The 12-year cumulative incidences of IBTR and oLRR in patients treated with adjuvant systemic therapy were 6.6% and 1.8%, respectively. Overall, 37.1% of IBTRs and 72.7% of oLRRs occurred within 5 years of diagnosis. Older age, black race, higher body mass index (BMI), larger tumors, and occurrence of IBTR or oLRR were significantly associated with increased mortality. The 5-year OS after IBTR and oLRR were 76.6% and 34.9%, respectively. Adjusted hazard ratios for mortality associated with IBTR and oLRR were significantly higher in estrogen receptor (ER)-negative patients than in ER-positive patients (P = .002 and P < .0001, respectively). Patients with early LRF had worse OS and DDFI than those with later-occurring LRF.

Conclusion: Although LRF is uncommon in patients with node-negative breast cancer who are treated with lumpectomy, radiation, and adjuvant systemic therapy, those who do develop LRF have substantially worse OS and DDFI.

PubMed Disclaimer

Conflict of interest statement

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Figures

Fig 1.
Fig 1.
Outcomes after ipsilateral breast tumor recurrence (IBTR) and other locoregional recurrence (oLRR) by estrogen receptor (ER) status. (A) Distant-disease–free interval (DDFI) and (B) overall survival (OS) for the first 5 years after IBTR by ER status; and (C) DDFI and (D) OS for the first 5 years after oLRR by ER status. The total numbers of events and deaths are measured during all follow-up time after the diagnosis of IBTR or oLRR.
Fig A1.
Fig A1.
Cumulative incidence of ipsilateral breast tumor recurrence (IBTR) in lumpectomy patients in five node-negative National Surgical Adjuvant Breast and Bowel Project protocols for known values of (A) age at surgery; (B) ethnicity; (C) clinical tumor size (CTS); (D) pathologic tumor size (PTS); (E) estrogen receptor (ER) status; and (F) assigned adjuvant therapy. The numbers of events are measured during all follow-up time. Rx, treatment; Tam, tamoxifen; Chemo, chemotherapy.
Fig A2.
Fig A2.
Cumulative incidence of other locoregional recurrence (oLRR) in lumpectomy patients in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative disease by (A) age at surgery; (B) race; (C) clinical tumor size (CTS); (D) pathologic tumor size (PTS); (E) estrogen receptor (ER) status; and (F) assigned adjuvant therapy. The numbers of events are measured during all follow-up time. Rx, treatment; Tam, tamoxifen; Chemo, chemotherapy.
See this image and copyright information in PMC

Comment in

References

    1. Fisher B, Anderson S, Fisher ER, et al. Significance of ipsilateral breast tumour recurrence after lumpectomy. Lancet. 1991;338:327–331. - PubMed
    1. Haffty B, Fischer D, Beinfield M, et al. Prognosis following local recurrence in the conservatively treated breast cancer patient. Int J Radiat Oncol Biol Phys. 1991;21:293–298. - PubMed
    1. Fisher ER, Anderson S, Redmond C, et al. Ipsilateral breast tumor recurrence and survival following lumpectomy and irradiation: Pathological findings from NSABP protocol B-06. Semin Surg Oncol. 1992;8:161–166. - PubMed
    1. Veronesi U, Marubini E, Del Vecchio M, et al. Local recurrences and distant metastases after conservative breast cancer treatments: Partly independent events. J Natl Cancer Inst. 1995;87:19–27. - PubMed
    1. Haffty BG, Reiss M, Beinfield M, et al. Ipsilateral breast tumor recurrence as a predictor of distant disease: Implications for systemic therapy at the time of local relapse. J Clin Oncol. 1996;14:52–57. - PubMed

Publication types